Federated Hermes, Inc. Myriad Genetics Inc Transaction History

Federated Hermes, Inc.

  • $43.9 Billion
  • Q1 2025

A detailed history of Federated Hermes, Inc. transactions in Myriad Genetics Inc stock. As of the latest transaction made, Federated Hermes, Inc. holds 1,079 shares of MYGN stock, worth $5,308. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,079
Previous 8,600 87.45%
Holding current value
$5,308
Previous $117,000 92.31%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 08, 2025
SELL
$8.87 - $14.98 $66,711 - $112,664
-7,521 Reduced 87.45%
1,079 $9,000
Q4 2024

Feb 13, 2025
SELL
$13.17 - $27.03 $632,146 - $1.3 Million
-47,999 Reduced 84.81%
8,600 $117,000
Q3 2024

Nov 13, 2024
SELL
$23.97 - $28.6 $4,985 - $5,948
-208 Reduced 0.37%
56,599 $1.55 Million
Q2 2024

Aug 08, 2024
BUY
$17.98 - $25.47 $15,211 - $21,547
846 Added 1.51%
56,807 $1.39 Million
Q1 2024

May 14, 2024
BUY
$17.59 - $23.59 $16,745 - $22,457
952 Added 1.73%
55,961 $1.19 Million
Q4 2023

Jan 31, 2024
SELL
$13.91 - $21.32 $21,324 - $32,683
-1,533 Reduced 2.71%
55,009 $1.05 Million
Q3 2023

Nov 13, 2023
SELL
$15.99 - $23.22 $15 - $23
-1 Reduced -0.0%
56,542 $906,000
Q2 2023

Aug 14, 2023
SELL
$17.56 - $23.76 $30,519 - $41,294
-1,738 Reduced 2.98%
56,543 $1.31 Million
Q1 2023

May 08, 2023
BUY
$15.26 - $23.75 $27,178 - $42,298
1,781 Added 3.15%
58,281 $1.35 Million
Q4 2022

Feb 13, 2023
BUY
$14.51 - $20.99 $15,191 - $21,976
1,047 Added 1.89%
56,500 $819,000
Q3 2022

Nov 14, 2022
SELL
$18.21 - $27.88 $396,286 - $606,724
-21,762 Reduced 28.18%
55,453 $1.06 Million
Q2 2022

Aug 15, 2022
SELL
$16.45 - $25.88 $568,627 - $894,593
-34,567 Reduced 30.92%
77,215 $1.4 Million
Q1 2022

May 13, 2022
SELL
$22.67 - $28.01 $239,100 - $295,421
-10,547 Reduced 8.62%
111,782 $2.82 Million
Q4 2021

Feb 14, 2022
BUY
$24.13 - $32.63 $712,655 - $963,694
29,534 Added 31.83%
122,329 $3.38 Million
Q3 2021

Nov 15, 2021
BUY
$29.97 - $36.66 $827,981 - $1.01 Million
27,627 Added 42.39%
92,795 $3 Million
Q2 2021

Aug 16, 2021
SELL
$25.39 - $32.61 $6,576 - $8,445
-259 Reduced 0.4%
65,168 $1.99 Million
Q1 2021

May 13, 2021
SELL
$19.92 - $31.6 $135,615 - $215,132
-6,808 Reduced 9.42%
65,427 $1.99 Million
Q4 2020

Feb 12, 2021
SELL
$12.16 - $19.77 $8.27 Million - $13.4 Million
-679,748 Reduced 90.39%
72,235 $1.43 Million
Q3 2020

Nov 12, 2020
SELL
$11.25 - $14.75 $6.86 Million - $8.99 Million
-609,441 Reduced 44.76%
751,983 $9.81 Million
Q2 2020

Aug 13, 2020
BUY
$10.69 - $16.49 $6.25 Million - $9.63 Million
584,219 Added 75.17%
1,361,424 $15.4 Million
Q1 2020

May 13, 2020
BUY
$9.78 - $29.53 $7.6 Million - $23 Million
777,205 New
777,205 $11.1 Million
Q3 2019

Nov 14, 2019
SELL
$22.08 - $47.08 $2.7 Million - $5.75 Million
-122,085 Closed
0 $0
Q2 2019

Aug 14, 2019
BUY
$22.67 - $35.0 $874,381 - $1.35 Million
38,570 Added 46.18%
122,085 $3.39 Million
Q1 2019

May 10, 2019
SELL
$26.93 - $34.7 $1.06 Million - $1.36 Million
-39,212 Reduced 31.95%
83,515 $2.77 Million
Q4 2018

Feb 13, 2019
SELL
$27.23 - $45.56 $2.86 Million - $4.79 Million
-105,192 Reduced 46.15%
122,727 $3.57 Million
Q3 2018

Nov 13, 2018
BUY
$37.57 - $50.34 $600,857 - $805,087
15,993 Added 7.55%
227,919 $10.5 Million
Q2 2018

Aug 10, 2018
BUY
$27.75 - $40.17 $3.21 Million - $4.65 Million
115,784 Added 120.43%
211,926 $7.92 Million
Q1 2018

May 09, 2018
BUY
$28.83 - $41.01 $2.67 Million - $3.79 Million
92,478 Added 2523.96%
96,142 $2.84 Million
Q3 2017

Nov 13, 2017
BUY
$24.01 - $36.2 $87,972 - $132,636
3,664
3,664 $133,000

Others Institutions Holding MYGN

# of Institutions
240
Shares Held
95.3M
Call Options Held
95.4K
Put Options Held
18.2K
View Full List

About MYRIAD GENETICS INC

MYGN Quotes by TradingView
  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $397M
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email